GLS 5310
Alternative Names: GLS-5310; GLS-5310 DNA plasmid vaccine; GLS-5310 DNA vaccineLatest Information Update: 02 Dec 2024
At a glance
- Originator GeneOne Life Science
- Class COVID-19 vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 20 Oct 2021 GeneOne Life Science plans phase I trial for COVID-2019 infections (Prevention) in Puerto Rico (Intradermal) (Intranasal) in November 2021 (NCT05085639)
- 23 Dec 2020 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in South Korea (Intradermal) (NCT04673149)
- 17 Dec 2020 GeneOne Life Science plans a phase I/II trial for COVID-2019 infections (Prevention, In adults) in South Korea (Intradermal) in December 2020 (NCT04673149)